|
|
 |
 |
|  |  |
 |  |  |  |  |
organism-gene
 |


|
 PR:O43291 |
   Kunitz-type protease inhibitor 2 (human)
 |
   hSPINT2
 |
  "A Kunitz-type protease inhibitor 2 that is encoded in the genome of human." [PRO:DNx, UniProtKB:O43291]
 |

| 
|
|
|
 |
 |
|  |  |  |  |
 |  |  |
organism-sequence
 |


|
 PR:O43291-1 |
   Kunitz-type protease inhibitor 2 isoform 1 (human)
 |
   hSPINT2/iso:1
 |
  "A Kunitz-type protease inhibitor 2 isoform 1 that is encoded in the genome of human." [PRO:DNx]
 |

| 
|
|
|
 |
 |
|  |  |  |  |
 |  |  |
organism-sequence
 |


|
 PR:O43291-2 |
   Kunitz-type protease inhibitor 2 isoform 2 (human)
 |
   hSPINT2/iso:2
 |
  "A Kunitz-type protease inhibitor 2 isoform 2 that is encoded in the genome of human." [PRO:DNx]
 |

| 
|
|
|
 |
 |
|  |  |  |  |
 |  |  |
organism-modification
 |


|
 PR:000049327 |
   Kunitz-type protease inhibitor 2, signal peptide removed form (human)
 |
   hSPINT2/SigPep-
 |
  "A Kunitz-type protease inhibitor 2 (human) that has had the signal peptide removed. UniProtKB:O43291, 28-252." [PRO:DNx, Reactome:R-HSA-6800233]
 |

| 
|
|
|
 |
 |
|  |  |  |  |
 |  |  |
organism-modification
 |


|
 PR:000050740 |
   Kunitz-type protease inhibitor 2 O-glycosylated 1 (human)
 |
   hSPINT2/OGlyco:1
 |
  "A Kunitz-type protease inhibitor 2 (human) that has been O-glycosylated at the residue equivalent to Thr-134 of the amino acid sequence represented by UniProtKB:O43291-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:O43291-1, Thr-134, MOD:00005~GNO:G43417UB." [GlyGen:O43291-1, PMID:30459171, PRO:DNx]
 |

| 
|
|
|
 |
 |
|  |  |  |  |
 |  |  |
organism-modification
 |


|
 PR:000082526 |
   Kunitz-type protease inhibitor 2 cysteinylated 1 (human)
 |
   hSPINT2/Cyst:1
 |
  "A Kunitz-type protease inhibitor 2 (human) that has been cysteinylated on the residue at the position equivalent to Cys-142 of the amino acid sequence represented by UniProtKB:O43291-1. Example: UniProtKB:O43291-1, Cys-142, MOD:00765." [IEDB_epitope:1334289, PRO:DNx]
 |

| 
|
|
|